nodgoРоссийский журнал детской гематологии и онкологии (РЖДГиО)Russian Journal of Pediatric Hematology and Oncology2311-12672413-5496LTD “Graphica”10.21682/2311-1267-2026-13-1-129-132nodgo-1255Research ArticleРЕЗОЛЮЦИИRESOLUTIONSСателлитный симпозиум «Классика и авангард в иммунотерапии нейробластомы высокого риска»Satellite Symposium “Classic and avant-garde in immunotherapy of high-risk neuroblastoma”РедакционнаястатьяEditorialArticle202603042026131129132Copyright © Редакционная с., 20262026Редакционная с.Editorial a.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nodgo.org/jour/article/view/1255
.
ReferencesНациональные клинические рекомендации. Нейробластома. Версия 2024 г. [Электронный ресурс]: https://cr.minzdrav.gov.ru/view-cr/78_2.National clinical guidelines. Neuroblastoma. Version 2024. [Electronic resource]: https://cr.minzdrav.gov.ru/view-cr/78_2. (In Russ.).Yu A.L., Gilman A.L., Ozkaynak M.F., London W.B., Kreissman S.G., Chen H.X., Smith M., Anderson B., Villablanca J.G., Matthay K.K., Shimada H., Grupp S.A., Seeger R., Reynolds C.P., Buxton A., Reisfeld R.A., Gillies S.D., Cohn S.L., Maris J.M., Sondel P.M.; Childrenʼs Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363(14):1324–34. doi: 10.1056/NEJMoa0911123.Yu A.L., Gilman A.L., Ozkaynak M.F., London W.B., Kreissman S.G., Chen H.X., Smith M., Anderson B., Villablanca J.G., Matthay K.K., Shimada H., Grupp S.A., Seeger R., Reynolds C.P., Buxton A., Reisfeld R.A., Gillies S.D., Cohn S.L., Maris J.M., Sondel P.M.; Childrenʼs Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363(14):1324–34. doi: 10.1056/NEJMoa0911123.Yu A.L., Gilman A.L., Ozkaynak M.F., Naranjo A., Diccianni M.B., Gan J., Hank J.A., Batova A., London W.B., Tenney S.C., Smith M., Shulkin B.L., Parisi M., Matthay K.K., Cohn S.L., Maris J.M., Bagatell R., Park J.R., Sondel P.M. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. Clin Cancer Res. 2021;27(8):2179–89. doi: 10.1158/1078-0432.CCR-20-3909.Yu A.L., Gilman A.L., Ozkaynak M.F., Naranjo A., Diccianni M.B., Gan J., Hank J.A., Batova A., London W.B., Tenney S.C., Smith M., Shulkin B.L., Parisi M., Matthay K.K., Cohn S.L., Maris J.M., Bagatell R., Park J.R., Sondel P.M. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. Clin Cancer Res. 2021;27(8):2179–89. doi: 10.1158/1078-0432.CCR-20-3909.Desai A.V., Gilman A.L., Ozkaynak M.F., Naranjo A., London W.B., Tenney S.C., Diccianni M., Hank J.A., Parisi M.T., Shulkin B.L., Smith M., Moscow J.A., Shimada H., Matthay K.K., Cohn S.L., Maris J.M., Bagatell R., Sondel P.M., Park J.R., Yu A.L. Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Childrenʼs Oncology Group. J Clin Oncol. 2022;40(35):4107–18. doi: 10.1200/JCO.21.02478.Desai A.V., Gilman A.L., Ozkaynak M.F., Naranjo A., London W.B., Tenney S.C., Diccianni M., Hank J.A., Parisi M.T., Shulkin B.L., Smith M., Moscow J.A., Shimada H., Matthay K.K., Cohn S.L., Maris J.M., Bagatell R., Sondel P.M., Park J.R., Yu A.L. Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Childrenʼs Oncology Group. J Clin Oncol. 2022;40(35):4107–18. doi: 10.1200/JCO.21.02478.Desai A.V., Naranjo A., LaBarre B., Chen L., Goldsmith K.C., Granger M.P., States L., Green S.G., Trunzo M., Fitzgerald W., DuBois S.G., Bagatell R., Park J.R., Marachelian A. A pilot study of chemoimmunotherapy in the postconsolidation setting for high-risk neuroblastoma (ANBL19P1): A report from the Childrenʼs Oncology Group. Cancer. 2026;132(2):e70165. doi: 10.1002/cncr.70165.Desai A.V., Naranjo A., LaBarre B., Chen L., Goldsmith K.C., Granger M.P., States L., Green S.G., Trunzo M., Fitzgerald W., DuBois S.G., Bagatell R., Park J.R., Marachelian A. A pilot study of chemoimmunotherapy in the postconsolidation setting for high-risk neuroblastoma (ANBL19P1): A report from the Childrenʼs Oncology Group. Cancer. 2026;132(2):e70165. doi: 10.1002/cncr.70165.Simon T., Thole T., Castelli S., Timmermann B., Jazmati D., Schwarz R., Fuchs J., Warmann S., Hubertus J., Schmidt M., Rogasch J., Körber F., Vokuhl C., Schäfer J., Schulte J.H., Deubzer H., Rosswog C., Fischer M., Lang P., Langer T., Astrahantseff K., Lode H., Hero B., Eggert A. GPOH Guidelines for Diagnosis and First-line Treatment of Patients with Neuroblastic Tumors, update 2025. Klin Padiatr. 2025;237(3):117–40. doi: 10.1055/a-2556-4302. Erratum in: Klin Padiatr. 2025;237(3):e3. doi: 10.1055/a-2623-7760.Simon T., Thole T., Castelli S., Timmermann B., Jazmati D., Schwarz R., Fuchs J., Warmann S., Hubertus J., Schmidt M., Rogasch J., Körber F., Vokuhl C., Schäfer J., Schulte J.H., Deubzer H., Rosswog C., Fischer M., Lang P., Langer T., Astrahantseff K., Lode H., Hero B., Eggert A. GPOH Guidelines for Diagnosis and First-line Treatment of Patients with Neuroblastic Tumors, update 2025. Klin Padiatr. 2025;237(3):117–40. doi: 10.1055/a-2556-4302. Erratum in: Klin Padiatr. 2025;237(3):e3. doi: 10.1055/a-2623-7760.Furman W.L., Federico S.M., McCarville M.B., Shulkin B.L., Davidoff A.M., Krasin M.J., Sahr N., Sykes A., Wu J., Brennan R.C., Bishop M.W., Helmig S., Stewart E., Navid F., Triplett B., Santana V.M., Bahrami A., Anthony G., Yu A.L., Hank J., Gillies S.D., Sondel P.M., Leung W.H., Pappo A.S. A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma. Clin Cancer Res. 2019;25(21):6320–8. doi: 10.1158/1078-0432.CCR-19-1452.Furman W.L., Federico S.M., McCarville M.B., Shulkin B.L., Davidoff A.M., Krasin M.J., Sahr N., Sykes A., Wu J., Brennan R.C., Bishop M.W., Helmig S., Stewart E., Navid F., Triplett B., Santana V.M., Bahrami A., Anthony G., Yu A.L., Hank J., Gillies S.D., Sondel P.M., Leung W.H., Pappo A.S. A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma. Clin Cancer Res. 2019;25(21):6320–8. doi: 10.1158/1078-0432.CCR-19-1452.Furman W.L., McCarville B., Shulkin B.L., Davidoff A., Krasin M., Hsu C.W., Pan H., Wu J., Brennan R., Bishop M.W., Helmig S., Stewart E., Navid F., Triplett B., Santana V., Santiago T., Hank J.A., Gillies S.D., Yu A., Sondel P.M., Leung W.H., Pappo A., Federico S.M. Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A. J Clin Oncol. 2022;40(4):335–44. doi: 10.1200/JCO.21.01375.Furman W.L., McCarville B., Shulkin B.L., Davidoff A., Krasin M., Hsu C.W., Pan H., Wu J., Brennan R., Bishop M.W., Helmig S., Stewart E., Navid F., Triplett B., Santana V., Santiago T., Hank J.A., Gillies S.D., Yu A., Sondel P.M., Leung W.H., Pappo A., Federico S.M. Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A. J Clin Oncol. 2022;40(4):335–44. doi: 10.1200/JCO.21.01375.Gray J.C., Weston R., Owens C., Canete A., Gambart M., De Wilde B., Nysom K., van Eijkelenburg N., Ladenstein R., Castellano A., Gerber N.U., Marshall L.V., Barone G., Rubio-San-Simon A., Ng A., Vaidya S., Gallego S., Makin G., Burke G.A.A., McCarthy A., Murphy D., Zwaan C.M., López-Almaraz R., Jannier S., Thebaud E., Corradini N., Yeomanson D., Howell L., Tweddle D.A., Elliott M., Hobin D., Valteau-Couanet D., Schleiermacher G., Chastagner P., Defachelles A.S., Brichard B., George S., Chesler L., Laidler J., Firth C., Holt G., Moroz V., Pearson A.D.J., Gates S., Wheatley K., Kearns P., Moreno L. Dinutuximab Beta Added to TemozolomideBased Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial. J Clin Oncol. 2026;44(3):176–87. doi: 10.1200/JCO-25-01868.Gray J.C., Weston R., Owens C., Canete A., Gambart M., De Wilde B., Nysom K., van Eijkelenburg N., Ladenstein R., Castellano A., Gerber N.U., Marshall L.V., Barone G., Rubio-San-Simon A., Ng A., Vaidya S., Gallego S., Makin G., Burke G.A.A., McCarthy A., Murphy D., Zwaan C.M., López-Almaraz R., Jannier S., Thebaud E., Corradini N., Yeomanson D., Howell L., Tweddle D.A., Elliott M., Hobin D., Valteau-Couanet D., Schleiermacher G., Chastagner P., Defachelles A.S., Brichard B., George S., Chesler L., Laidler J., Firth C., Holt G., Moroz V., Pearson A.D.J., Gates S., Wheatley K., Kearns P., Moreno L. Dinutuximab Beta Added to TemozolomideBased Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial. J Clin Oncol. 2026;44(3):176–87. doi: 10.1200/JCO-25-01868.Berlanga P., Pasqualini C., Gambart M., Dumont B., Thebaud E., Tandonnet J., Benadiba J., Leruste A., Coze C., Schleiermacher G., Defachelles A.S. Recommandations du Comité neuroblastome de la Société française de lutte contre les cancers et les leucémies de l’enfant et de l’adolescent pour la prise en charge des patients présentant un neuroblastome de haut risque en rechute/progression [Treatment guidelines for patients with relapsed/progressive high-risk neuroblastoma from the Neuroblastoma Committee of the French Society of Pediatric Oncology]. Bull Cancer. 2025;112(9):1035–44. doi: 10.1016/j.bulcan.2025.04.006.Berlanga P., Pasqualini C., Gambart M., Dumont B., Thebaud E., Tandonnet J., Benadiba J., Leruste A., Coze C., Schleiermacher G., Defachelles A.S. Recommandations du Comité neuroblastome de la Société française de lutte contre les cancers et les leucémies de l’enfant et de l’adolescent pour la prise en charge des patients présentant un neuroblastome de haut risque en rechute/progression [Treatment guidelines for patients with relapsed/progressive high-risk neuroblastoma from the Neuroblastoma Committee of the French Society of Pediatric Oncology]. Bull Cancer. 2025;112(9):1035–44. doi: 10.1016/j.bulcan.2025.04.006.Castelli S., Schulze F., Thole-Kliesch T.M., Astrahantseff K., Barone G., Beck-Popovic M., Berlanga P., Corbacioglu S., Fischer M., Gambart M., George S.L., Chesler L., Gray J.C., Hero B., Künkele A., Flaadt T., Lang P., Lode H.N., Molenaar J.J., Schleiermacher G., Rosswog C., Moreno L., Owens C., Rubio-San-Simón A., Schulte J.H., Simon T., Tweddle D.A., Deubzer H.E., Eggert A.; SIOPEN New Drug Development, Immunotherapy and Relapse Groups. Current treatment strategies for first relapse of high-risk neuroblastoma. Eur J Cancer. 2026;236:116254. doi: 10.1016/j.ejca.2026.116254.Castelli S., Schulze F., Thole-Kliesch T.M., Astrahantseff K., Barone G., Beck-Popovic M., Berlanga P., Corbacioglu S., Fischer M., Gambart M., George S.L., Chesler L., Gray J.C., Hero B., Künkele A., Flaadt T., Lang P., Lode H.N., Molenaar J.J., Schleiermacher G., Rosswog C., Moreno L., Owens C., Rubio-San-Simón A., Schulte J.H., Simon T., Tweddle D.A., Deubzer H.E., Eggert A.; SIOPEN New Drug Development, Immunotherapy and Relapse Groups. Current treatment strategies for first relapse of high-risk neuroblastoma. Eur J Cancer. 2026;236:116254. doi: 10.1016/j.ejca.2026.116254.Raiser P., Schleiermacher G., Gambart M., Dumont B., Defachelles A.S., Thebaud E., Tandonnet J., Pasqualini C., Proust S., Entz-Werle N., Aerts I., Ndounga-Diakou L.A., Petit A., Puiseux C., Khanfar C., Rouger J., Mansuy L., Benadiba J., Millot F., Pluchart C., Laghouati S., Geoerger B., Vassal G., Valteau-Couanet D., Berlanga P. Chemo-immunotherapy with dinutuximab beta in patients with relapsed/progressive high-risk neuroblastoma: does chemotherapy backbone matter? Eur J Cancer. 2024;202:114001. doi: 10.1016/j.ejca.2024.114001.Raiser P., Schleiermacher G., Gambart M., Dumont B., Defachelles A.S., Thebaud E., Tandonnet J., Pasqualini C., Proust S., Entz-Werle N., Aerts I., Ndounga-Diakou L.A., Petit A., Puiseux C., Khanfar C., Rouger J., Mansuy L., Benadiba J., Millot F., Pluchart C., Laghouati S., Geoerger B., Vassal G., Valteau-Couanet D., Berlanga P. Chemo-immunotherapy with dinutuximab beta in patients with relapsed/progressive high-risk neuroblastoma: does chemotherapy backbone matter? Eur J Cancer. 2024;202:114001. doi: 10.1016/j.ejca.2024.114001.Gong Z., Kang S., Bai C., Li Y., Yu X., Shang K., Song Y., Cheng F., Wang J. Extended cycles of anti-GD2 antibody dinutuximab beta treatment combined with chemotherapy in patients with relapsed or refractory neuroblastoma: A retrospective study. Oncol Lett. 2025;31(2):85. doi: 10.3892/ol.2025.15438.Gong Z., Kang S., Bai C., Li Y., Yu X., Shang K., Song Y., Cheng F., Wang J. Extended cycles of anti-GD2 antibody dinutuximab beta treatment combined with chemotherapy in patients with relapsed or refractory neuroblastoma: A retrospective study. Oncol Lett. 2025;31(2):85. doi: 10.3892/ol.2025.15438.
The authors declare that there are no conflicts of interest present.